Alternative psoriasis screening model

Imiquimod induced Psoriasis

 A TH17 driven psoriasis-like inflammation

Imiquimod (IMQ)-induced psoriasis model - a good alternative screening model to more complex psoriasis models.

The IMQ-induced psoriasis model contains a strong T cell component. IMQ is a ligand for TLR7 and TLR8 that when applied topically to the skin, induces psoriasis-like inflammation in susceptible humans and mice. Our scientists have studied how the application of IMQ on the skin results in an influx of various cells of the immune system, as well as hyperplasia of the epidermis. The IMQ-psoriasis closely resembles human psoriasis lesions in terms of phenotypic and histological characteristics and the lesion development is dependent on IL-12 and IL-17.  Read our Whitepaper to learn more about why the IMQ-induced psoriasis model is a good alternative to more complex psoriasis models. 


In the IMQ-induced psoriasis model whitepaper, we review:

  • Background and pathology of psoriasis 
  • What constitutes a good preclinical model of psoriasis
  • Imiquimod-induced model overview
  • Data including psoriasis scores, spleen weight and cellular composition, histology and biomarkers
  • How the IMQ-induced model correlates to human psoriasis


The Imiquimod-induced psoriasis-like inflammation model is based on a single innate antigenic receptor ligand. Since it requires no adjuvants, it is considered a clean model from an immunological viewpoint, resembling most of the features of human psoriatic lesions. It presents epidermal changes based on keratino- cyte hyperproliferation and altered differentiation, contains the presence of inflammatory cells including T cells, DC, and neutrophils; has a functional role for T cells and contains altered vascularity. Papillomatosis are sometimes observed. It’s dependence on IL-23, the resemblance of most features of human psoriatic lesions and its short duration makes it a convenient, cost-effective model for screening immunologically targeted therapies.


Download the Imiquimod (IMQ)-Induced Psoriasis Whitepaper now!